a2z Radiology AI Raises $4.5m Seed Round to Scale FDA-Cleared CT Imaging Platform
Boston-based medical imaging startup a2z Radiology AI has raised $4.5 million in a seed funding round as it moves to scale its artificial intelligence technology designed to support radiologists and improve diagnostic workflows. The funding follows a key regulatory milestone for the company, which has received U.S. Food and Drug Administration clearance for its a2z-Unified-Triage system, an AI product capable of identifying multiple urgent findings on abdomen–pelvis CT scans in a single analysis.
The seed round was co-led by Khosla Ventures, a venture capital firm known for backing early-stage companies at the intersection of artificial intelligence and healthcare, and SeaX Ventures, a global deep-tech investment firm focused on technologies with transformative potential. The participation of these investors reflects growing confidence in the role of AI-driven tools in addressing operational and clinical challenges within radiology departments.
Founded in 2024, a2z Radiology AI was created by Pranav Rajpurkar, PhD, an associate professor at Harvard Medical School with extensive research experience in medical imaging and machine learning, and Samir Rajpurkar, who serves as chief executive officer. The company’s mission is to develop comprehensive AI systems that assist radiologists by prioritising urgent cases and streamlining interpretation, rather than focusing on single-disease detection models that dominate much of the current medical imaging AI market.
The company’s first product, a2z-Unified-Triage, is designed to flag multiple acute conditions on CT scans of the abdomen and pelvis, helping clinicians quickly identify patients who may require immediate attention. By covering several findings in one system, the technology aims to reduce fragmentation in radiology workflows, where multiple AI tools are often required to address different clinical scenarios. This broader approach is positioned as a way to save time, improve efficiency and support consistent decision-making in busy clinical environments.
Proceeds from the seed round will be used to accelerate commercialization of the FDA-cleared product, expand partnerships with healthcare providers and support further research and development. a2z Radiology AI plans to invest in expanding its technology to additional imaging modalities and anatomical regions, as well as in strengthening its engineering and clinical teams. The company is also preparing for a broader commercial rollout, with a focus on integrating its tools into hospital and imaging center workflows.
The funding comes amid increasing pressure on radiology departments, driven by rising imaging volumes, workforce shortages and growing expectations for faster turnaround times. Abdomen–pelvis CT scans represent a significant share of imaging workloads, and tools that can help triage urgent findings more efficiently are seen as increasingly valuable. a2z Radiology AI’s multi-condition approach is intended to complement radiologist expertise rather than replace it, with the goal of reducing cognitive burden and enabling clinicians to focus on complex cases.
The company has also shared early evidence supporting the clinical value of its technology. Results presented at industry conferences have shown that the use of a2z Radiology AI’s system can reduce reporting times and improve radiologist confidence during image interpretation, while lowering perceived mental demand. These findings support the company’s belief that comprehensive AI tools can have a meaningful impact on day-to-day clinical practice.
Investor backing from Khosla Ventures and SeaX Ventures provides more than capital, bringing strategic guidance and experience in scaling AI-driven healthcare companies. Both firms have track records of supporting startups through regulatory, commercial and technical challenges, which are particularly significant in the medical imaging sector.
Since its formation, a2z Radiology AI has progressed rapidly from research to regulatory clearance and now to early commercialization. The seed funding is expected to give the company the runway needed to validate its business model, expand customer adoption and continue advancing its technology roadmap.
As interest in healthcare AI continues to grow, a2z Radiology AI is positioning itself as a company focused on breadth, integration and real-world clinical utility. With fresh funding in place, the startup aims to play a role in shaping how artificial intelligence is used to support radiologists and improve patient care across imaging departments.
